☰

Kristopher A. Lofgren, Ph.D. - Publications

Affiliations: 
2005-2010 Microbiology, Immunology, and Cancer Biology University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Lofgren KA, Kenny PA. Grb7 knockout mice develop normally but litters born to knockout females fail to thrive. Developmental Dynamics : An Official Publication of the American Association of Anatomists. PMID 38140940 DOI: 10.1002/dvdy.686  0.634
2022 Lofgren KA, Reker NC, Sreekumar S, Kenny PA. Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate. Antibody Therapeutics. 5: 226-231. PMID 36110096 DOI: 10.1093/abt/tbac020  0.69
2022 Parsons BM, Meier DR, Gurda GT, Lofgren KA, Kenny PA. Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor. Jco Precision Oncology. 1: 1-6. PMID 35172503 DOI: 10.1200/PO.17.00070  0.726
2021 Lofgren KA, Sreekumar S, Jenkins EC, Ernzen KJ, Kenny PA. Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer. Antibody Therapeutics. 4: 252-261. PMID 34877472 DOI: 10.1093/abt/tbab026  0.749
2020 Parsons BM, Meier DR, Richmond CS, Gurda GT, Lofgren KA, Burkard ME, Deming DA, Kenny PA. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. Clinical Breast Cancer. PMID 32234363 DOI: 10.1016/J.Clbc.2020.02.003  0.71
2019 Meier DR, Girtman MA, Lofgren KA, Kenny PA. Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice. Breast Cancer Research and Treatment. PMID 31838731 DOI: 10.1007/S10549-019-05507-2  0.741
2019 Lofgren K, Emmanuel N, Meier D, Kenny P. SAT-331 Elucidating the Role of Breast Cancer Specific GATA3 Mutation in Estrogen Receptor Positive Breast Cancer Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Sat-331  0.648
2019 Parsons BM, Meier DR, Sreekumar S, Richmond CS, Ernzen KJ, Lofgren KA, Deviley JA, Gurda GT, Kenny PA. Abstract 1317: Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations Cancer Research. 79: 1317-1317. DOI: 10.1158/1538-7445.Am2019-1317  0.614
2018 Emmanuel N, Lofgren KA, Peterson EA, Meier DR, Jung EH, Kenny PA. Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. Anticancer Research. 38: 4435-4441. PMID 30061207 DOI: 10.21873/Anticanres.12745  0.76
2018 Meier DR, Lofgren KA, Gurda GT, Kenny PA. Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors. Analytical Biochemistry. PMID 29752895 DOI: 10.1016/J.Ab.2018.05.007  0.696
2018 Parsons BM, Meier DR, Gurda GT, Lofgren KA, Kenny PA. Abstract 1822: Emergence of MET D1228N mutation as a resistance mechanism following an exceptional response to crizotinib in a MET-amplified triple-negative breast cancer patient Cancer Research. 78: 1822-1822. DOI: 10.1158/1538-7445.Am2018-1822  0.583
2017 Miller JJ, Lofgren KA, Hughes SR, Cash SE, Kenny PA. Genomic analysis of melanoma evolution following a 30 year disease-free interval. Journal of Cutaneous Pathology. PMID 28628281 DOI: 10.1111/Cup.12989  0.624
2017 Miller JJ, Lofgren KA, Hughes SR, Cash SE, Meier DR, Kenny PA. Abstract 3399: Genomic analysis of melanoma evolution following a 30 year disease-free interval Cancer Research. 77: 3399-3399. DOI: 10.1158/1538-7445.Am2017-3399  0.326
2017 Lofgren KA, Meier DR, Cash SE, Kenny PA. Abstract 2827: Establishing a mouse model to investigate GRB7-mediated signaling in development and triple-negative breast cancer Cancer Research. 77: 2827-2827. DOI: 10.1158/1538-7445.Am2017-2827  0.61
2016 Lofgren KA, Kenny PA. An instructive ductal microenvironment is key for efficient in vivo modeling of estrogen receptor positive breast cancer Translational Cancer Research. 5. DOI: 10.21037/8863  0.646
2015 Peterson EA, Jenkins EC, Lofgren KA, Chandiramani N, Liu H, Aranda E, Barnett M, Kenny PA. Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer. Cancer Research. PMID 26527289 DOI: 10.1158/0008-5472.Can-15-0709  0.788
2015 Lofgren KA, Calvo V, Giricz O, Kenny PA. Abstract 723: GRB7 promotes doxorubicin resistance in triple-negative breast cancer cells via multiple signaling pathways Cancer Research. 75: 723-723. DOI: 10.1158/1538-7445.Am2015-723  0.589
2013 Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Research. 73: 5810-20. PMID 23928995 DOI: 10.1158/0008-5472.Can-13-0523  0.722
2013 Mammoto A, Mammoto T, Kanapathipillai M, Wing Yung C, Jiang E, Jiang A, Lofgren K, Gee EP, Ingber DE. Control of lung vascular permeability and endotoxin-induced pulmonary oedema by changes in extracellular matrix mechanics. Nature Communications. 4: 1759. PMID 23612300 DOI: 10.1038/Ncomms2774  0.487
2013 Anderson TMR, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ. Erratum: Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression (Cancer Research (2013) 73 (5810-20)) Cancer Research. 73. DOI: 10.1158/0008-5472.Can-13-2741  0.655
2012 Locatelli A, Lofgren KA, Daniel AR, Castro NE, Lange CA. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Hormones & Cancer. 3: 14-25. PMID 22124844 DOI: 10.1007/S12672-011-0097-Z  0.738
2011 Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Research : Bcr. 13: R89. PMID 21923922 DOI: 10.1186/Bcr2946  0.747
2007 Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Research. 67: 4199-209. PMID 17483331 DOI: 10.1158/0008-5472.Can-06-3409  0.726
Show low-probability matches.